< back

Roger K. Cady, MD, AQH
Board Member
Ozark, Missouri

Roger K. Cady, MD, AQH, was elected to the Board in February 1998. He served as the Associate Executive Chairman of the National Headache Foundation from 2010 to 2016.

Dr. Cady graduated from the Mayo Medical School (Rochester, Minnesota) and completed his residency in family medicine at St. Francis-Mayo (La Crosse, Wisconsin) in 1980. Fulfilling a Public Health Scholarship commitment, he began medical practice in the rural community of Hillsboro WI. In 1986, he became the medical director of the Shealy Institute, an internationally recognized program dedicated to the holistic management of pain and chronic disease in Springfield, MO.

In 1993, he was the lead investigator and first author of the pivotal study on sumatriptan (Imitrex), a novel break-through acute treatment for migraine, published in the Journal of the American Medical Association (JAMA). This propelled Dr. Cady to become a key thought leader in the medical specialty of headache.

In 1996, he founded the Headache Care Center (Springfield, Missouri) and developed an intensive outpatient inter-disciplinary care model for managing patients living with migraine. The same year, he founded Clinvest, the research arm of his corporation. He designed several investigator-initiated studies that fostered large comprehensive national research trials and were instrumental in expanding the understanding of migraine from a benign self-limited episodic disorder into a potentially pervasive chronic disease.

With Kathleen Farmer-Cady, PsyD, his wife, and medical partner, he founded Primary Care Network (PCN), a nonprofit corporation dedicated to CME education, that initially was devoted solely to migraine. PCN provided hundreds of clinicians with in-depth education on diagnosis, pathophysiology, and treatment of migraine. Many headache specialists today attribute their educational experience with PCN as pivotal in their decision to pursue headache as an integral part of their medical practice.

As a member of the Board of Directors of the National Headache Foundation (NHF) and a Fellow of the American Headache Society, he has been actively involved in the clinical advancement of patient-center care, collaborative care models for migraine, and advancing clinically-based headache research.

He has designed and participated in approximately 300 clinical trials primarily evaluating novel migraine therapies and treatments. His work has been recognized as instrumental in defining the role of triptans in the acute treatment of migraine; defining the clinical spectrum of migraine; the early intervention paradigm for acute treatment; clarifying the relationship between migraine and “sinus” headache; the role of CGRP in chronification of migraine and temporal mandibular disfunction; and improving communication between patients and healthcare providers. And has authored approximately 400 scientific articles.

He was awarded a Lifetime Achievement Award by the National Headache Foundation (2012) and the Harold Wolff Award (2000) from the American Headache Society for his research on the spectrum of migraine.

In 2016, Alder Biopharmaceuticals offered Dr. Cady an opportunity to assist in designing the clinical studies leading to FDA approval of eptinezumab (Vyepti), a monoclonal antibody for the prevention of migraine. These clinical studies were the first to demonstrate day-one efficacy for a migraine preventive drug; efficacy of a monoclonal antibody in patients with a dual diagnosis of chronic migraine and Medication Overuse Headache; validation of a novel patient-specified most bothersome symptom as a patient-reported outcome measure, and recently the positive impact of preventive treatment administered during an active migraine attack.

Dr. Cady has authored multiple publications in major medical journals such as JAMA, Neurology, Headache, and Cephalalgia advancing current treatment paradigms for the prevention of migraine. Current interests include furthering the clinical development of eptinezumab. redefining preventive treatment goals for chronic migraine. and treatment of concussion.

He and his wife, Dr. Kathy Farmer-Cady, reside in Ozark, Missouri.

Subscribe to our Monthly e-Newsletter

Gain access to the most current migraine and headache information, prevention,

treatment, research, and news.